» Articles » PMID: 11003620

Up-regulation of Fas Ligand at Early Stages and Down-regulation of Fas at Progressed Stages of Intrahepatic Cholangiocarcinoma Reflect Evasion from Immune Surveillance

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2000 Sep 26
PMID 11003620
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

We examined immunohistochemically the possible participation of the Fas/Fas ligand (FasL) system in intrahepatic cholangiocarcinoma (ICC) during the escape from immune surveillance, using 68 cases of ICC, 29 cases of normal intrahepatic large bile ducts, and 18 cases of biliary dysplasia. Apoptosis of tumor-infiltrating lymphocytes (TIL) was examined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL). Fas was weakly expressed in normal intrahepatic bile ducts. Almost all biliary dysplasia and well-differentiated ICCs showed moderate to marked expression of Fas, while Fas expression was variable in moderately and poorly differentiated ICCs. Down-regulation of Fas expression was significantly correlated with histologic de-differentiation, vascular invasion, the size of ICCs, and short survival of ICC patients. By in situ hybridization, FasL mRNA were frequently and strongly expressed in biliary dysplasia compared with non-neoplastic intrahepatic bile duct. In well-differentiated ICCs, FasL mRNA expression was frequent and intense. But, the expression gradually decreased in moderately and poorly differentiated ICCs. Down-regulation of FasL mRNA expression in ICCs was correlated with perineural invasion and tumor size (over 4 cm) (P <.05). Apoptotic TIL were more frequent in ICC foci than in non-neoplastic foci remote from ICC foci. These findings suggest that a tumor evasion mechanism involving Fas/FasL exists in ICC; frequent and intense expression of FasL mRNA in well-differentiated ICCs enable them to escape immune surveillance by counterattacking Fas-bearing TIL. This counterattack becomes insensitive in poorly differentiated ICCs, in which the down-regulation of Fas gives them a resistance against the FasL-expressing TIL. These mechanisms may be involved in the tumor progression.

Citing Articles

Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes.

Li C, Bie L, Chen M, Ying J Explor Target Antitumor Ther. 2024; 4(6):1310-1327.

PMID: 38213535 PMC: 10776604. DOI: 10.37349/etat.2023.00199.


Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.

Annuar A, Ankathil R, Mohd Yunus N, Husin A, Ab Rajab N, Abdul Aziz A Asian Pac J Cancer Prev. 2021; 22(2):565-571.

PMID: 33639675 PMC: 8190357. DOI: 10.31557/APJCP.2021.22.2.565.


Genomic variants in Fas-mediated apoptosis pathway predict a poor response to Platinum-based Chemotherapy for Chinese Gastric Cancer Patients.

Zhao T, Li W, Chen J, Qin W J Cancer. 2021; 12(3):849-859.

PMID: 33403042 PMC: 7778532. DOI: 10.7150/jca.48120.


Genetic variations in the gene alter the risk of cervical cancer and precancerous lesions.

Dardiotis E, Siokas V, Garas A, Paraskevaidis E, Kyrgiou M, Xiromerisiou G Oncol Lett. 2018; 16(3):3833-3841.

PMID: 30127996 PMC: 6096185. DOI: 10.3892/ol.2018.9104.


Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity.

Lin G, Lin K, Wang F, Chen T, Yen T, Yeh T Dis Model Mech. 2018; 11(8).

PMID: 29666220 PMC: 6124555. DOI: 10.1242/dmm.033050.